Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEST: Sulforaphane in COPD
NCT01335971Phase 2Completed
- Sponsor
- Johns Hopkins University
- Start
- Sep 2010
- Primary completion
- Jul 2013
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sulforaphane in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by Johns Hopkins University. Primary endpoints: Change From Baseline in Alveolar Macrophage Expression of Nrf2 and Associated Genes at 4 weeks, Change From Baseline in Bronchial Epithelial Cell Expression of Nrf2 at 4 weeks and 1 more. Started Sep 2010; status: completed.
02
Drugs
sulforaphane
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT01335971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01335971.